Background Antiviral and antibody therapies for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are being recommended for high-risk patients, but the potential …

Anti-Spike monoclonal antibodies have been considered a promising approach to COVID-
19 therapy. Unfortunately, the advent of resistant lineages jeopardized their effectiveness …

Objectives To evaluate the impact of neutralizing monoclonal antibody (mAb) treatment and
to determine whether the selective pressure of mAbs could facilitate the proliferation of …

Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-
CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies …

Immunocompromised patients have an increased risk of persistent COVID‐19 disease. We
report here the clinical course of two patients with hematologic malignancies hospitalized …

Prolonged infections in immunocompromised individuals may be a source for novel Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, particularly when both …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Background Monoclonal antibody (mAb) treatment is associated with decreased risk of
hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

Dear Editor, SARS-CoV-2 inevitably evolves toward being more robust at multiplying. In the
herd immunity era, mutations allowing SARS-CoV-2 to bypass the immunity acquired from …